Drugs / DZD1516
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04509596 | Sep 2020 → Jul 2022 | breast cancer | Dizal Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DZD1516 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04509596 ↗ |
| Action | Inhibit | “DZD1516 is an oral, blood brain barrier penetrable, selective HER2 tyrosine kinase inhibitor.” NCT04509596 ↗ |
| Route | Oral | “Part A is twice daily (except Cycle 0) oral dosing of DZD1516, starting from 50 mg.” NCT04509596 ↗ |